Singapore, Oct. 30 -- DKSH has signed an agreement to acquire 100% of NewBridge Pharmaceuticals, a Dubai-headquartered healthcare commercialisation platform with operations across 14 markets in the MENA region, for an enterprise value of $390 million.

The acquisition represents a pivotal step in expanding DKSH Healthcare's footprint beyond Asia Pacific and advances DKSH Healthcare's strategic roadmap to become a leading multi-regional, end-to-end outsourcing platform.

It also aligns with DKSH's strategy to accelerate M&A. It enhances DKSH's offering as a single partner of choice for biopharmaceutical companies across a wider range of geographies and strengthens the commercialisation of innovative medicines for specialty and rare disease...